Patients with HR-positive/HER2-negative metastatic breast cancer (mBC) who receive antibody-drug conjugates (ADCs) have a unique spectrum of adverse events (AEs) that can lower quality of life (QoL). Patients and caregivers rely on health care providers for education and help managing the side effects of these emerging therapies. The third episode of this CEC BriefCase series continues to follow the same patient case and explores how to use shared decision making (SDM) to design strategies to monitor for and manage AEs in patients receiving ADCs
- Provider:Creative Educational Concepts, Inc.
- Activity Link: https://www.ceconcepts.com/activity/adcs-in-hr-her2-mbc-managing-aes/
- Start Date: 2024-07-31 05:00:00
- End Date: 2024-07-31 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Gilead Sciences, Inc. - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Medical Oncology
Subscribe
Login
0 Comments
Oldest